[(99m)Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial

BACKGROUND: [(99m)Tc]Tilmanocept, a novel CD206 receptor-targeted radiopharmaceutical, was evaluated in an open-label, phase III trial to determine the false negative rate (FNR) of sentinel lymph node biopsy (SLNB) relative to the pathologic nodal status in patients with intraoral or cutaneous head...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Amit, Civantos, Francisco J., Brumund, Kevin T., Chepeha, Douglas B., Hall, Nathan C., Carroll, William R., Smith, Russell B., Zitsch, Robert P., Lee, Walter T., Shnayder, Yelizaveta, Cognetti, David M., Pitman, Karen T., King, Dennis W., Christman, Lori A., Lai, Stephen Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Head and Neck Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565859/
https://www.ncbi.nlm.nih.gov/pubmed/25670018
http://dx.doi.org/10.1245/s10434-015-4382-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565859/
https://www.ncbi.nlm.nih.gov/pubmed/25670018
http://dx.doi.org/10.1245/s10434-015-4382-x

Ejemplares similares